GPRC5D-targeting chimeric antigen receptors: a new treatment for multiple myeloma?

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment for patients with relapsed or refractory multiple myeloma. A key aspect of developing effective CAR T-cell therapy is identifying the correct antigen, which specifically targets tumour cells and spares healthy tissue, thereby preventing on-target, off-tumour effects.1,2 Most clinical trials of CAR T-cell therapy for myeloma have investigated B-cell maturation antigen (BCMA) as an antigen target; these studies have led to approval of two BCMA-targeting CAR T products.